Heartseed (219A) · RiskRestated
Risks from technological innovation and intensifying competition
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: 2026-03-27.
3entries
2years
1from disclosures
How it moved
Same theme, other companies
Risk of Intensified Competition Due to Technological Innovation and Follow-on Entrants in Regenerative MedicineA theme 6 companies write about · 7 as a headwind · 0 as a tailwind
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-03-27RestatedManagement Planning
「If competitors develop new technologies that surpass our technology, among other circumstances, this could have a material impact on our business results and business development.」
The Company continued to disclose the risk of obsolescence resulting from technological innovation and competition. - FY2025RestatedAnnual report
「Research competition is intense worldwide in regenerative medicine, iPS cells and related fields, and dramatic technological innovation is progressing over short periods.」
The Company continues to disclose the risk of technological obsolescence and competitive disadvantage resulting from innovation and new entrants, together with the likelihood, timing and impact. - FY2024First statedAnnual report
「If innovative technologies are developed, existing technologies are substantially improved, technological innovation occurs in new treatments such as gene therapy, or new market entrants emerge, existing technologies may become obsolete.」
The Company identifies the risk that technological innovation or competitors' advances in regenerative medicine and iPS cells could make its technology obsolete and products difficult to sell.